Most Read Articles
Prof. Corinne Faivre-Finn, 30 Nov 2020
Consolidation therapy with the PD-L1 inhibitor durvalumab (Imfinzi®, AstraZeneca) following chemoradiation therapy (CRT) has become the standard of care in patients with unresectable stage III non-small-cell lung cancer (NSCLC), based on primary results of the PACIFIC study. The 4-year update of the study, presented recently at the European Society for Medical Oncology Virtual Congress 2020 (ESMO 2020), demonstrated durable and sustained survival benefits that were consistent with those reported in the primary analyses.
Dr. Roy Herbst, Dr. David Spigel, 09 Jul 2020
The third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) osimertinib is a standard of care in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Results of the ADAURA study, presented at the American Society of Clinical Oncology 2020 Virtual Scientific Programme (ASCO 2020), support earlier use of osimertinib in the adjuvant setting, with superior disease-free survival (DFS) in patients who underwent complete resection of stage IB/II/IIIA EGFR-positive NSCLC. 
Prof. Mark Shackleton, 01 Apr 2020
In recent years, the focus on immuno-oncology has generated a wealth of compelling evidence supporting the use of immune checkpoint inhibitors – in particular those targeting the programmed death-ligand 1 (PD-L1) or PD-1 pathway. At the 8th Oncology Summit organized by the Hong Kong Society of Clinical Oncology, Professor Mark Shackleton of Alfred Health and Monash University, Australia, discussed recent advances in immunotherapy for the management of metastatic Merkel cell carcinoma (MCC) with a focus on the role of the PD-L1 inhibitor avelumab.  
Dr. Keith Wong, 30 Nov 2020
The B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, has demonstrated promising efficacy in relapsed/refractory chronic lymphocytic leukaemia (CLL). However, the associated risk of tumour lysis syndrome (TLS) in certain patients necessitates prophylactic measures and close monitoring. In an interview with MIMS Oncology, Dr Keith Wong from the haematology department of a public hospital in Hong Kong discussed important treatment considerations for patients with CLL, and highlighted prophylactic and supportive measures established at his hospital to mitigate the risk of TLS complications associated with venetoclax-based therapy.

Rationale and clinical evidence for the use of tumour-treating fields in the treatment of glioblastoma and other cancers

24 Apr 2020
Tumour-treating fields (TTFields) are a non-invasive anticancer treatment modality that utilizes low-intensity, intermediate-frequency (100–300 kHz), alternating electric fields delivered through transducer arrays placed around the tumour region to inhibit tumour cell division.  

These TTFields affect various charged and polar molecules within rapidly dividing cancer cells. Through interfering with the structure of microtubules and the movement of organelles during cell division, TTFields cause abnormal mitosis, leading to cell death, blocking of cell division or the formation of lethal chromosomal aberrations. 

Sponsored as a service to the medical profession by Zailab Optune.Editorial development by MIMS MedComms.The opinions expressed in this publication are not necessarily those of the editor, publisher or sponsor.Any liability or obligation for loss or damage howsoever arising is hereby disclaimed.© 2020 MIMS (Hong Kong) Limited. All rights reserved.No part of this publication may be reproduced by any process in any language without the written permission of the publisher
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Prof. Corinne Faivre-Finn, 30 Nov 2020
Consolidation therapy with the PD-L1 inhibitor durvalumab (Imfinzi®, AstraZeneca) following chemoradiation therapy (CRT) has become the standard of care in patients with unresectable stage III non-small-cell lung cancer (NSCLC), based on primary results of the PACIFIC study. The 4-year update of the study, presented recently at the European Society for Medical Oncology Virtual Congress 2020 (ESMO 2020), demonstrated durable and sustained survival benefits that were consistent with those reported in the primary analyses.
Dr. Roy Herbst, Dr. David Spigel, 09 Jul 2020
The third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) osimertinib is a standard of care in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Results of the ADAURA study, presented at the American Society of Clinical Oncology 2020 Virtual Scientific Programme (ASCO 2020), support earlier use of osimertinib in the adjuvant setting, with superior disease-free survival (DFS) in patients who underwent complete resection of stage IB/II/IIIA EGFR-positive NSCLC. 
Prof. Mark Shackleton, 01 Apr 2020
In recent years, the focus on immuno-oncology has generated a wealth of compelling evidence supporting the use of immune checkpoint inhibitors – in particular those targeting the programmed death-ligand 1 (PD-L1) or PD-1 pathway. At the 8th Oncology Summit organized by the Hong Kong Society of Clinical Oncology, Professor Mark Shackleton of Alfred Health and Monash University, Australia, discussed recent advances in immunotherapy for the management of metastatic Merkel cell carcinoma (MCC) with a focus on the role of the PD-L1 inhibitor avelumab.  
Dr. Keith Wong, 30 Nov 2020
The B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, has demonstrated promising efficacy in relapsed/refractory chronic lymphocytic leukaemia (CLL). However, the associated risk of tumour lysis syndrome (TLS) in certain patients necessitates prophylactic measures and close monitoring. In an interview with MIMS Oncology, Dr Keith Wong from the haematology department of a public hospital in Hong Kong discussed important treatment considerations for patients with CLL, and highlighted prophylactic and supportive measures established at his hospital to mitigate the risk of TLS complications associated with venetoclax-based therapy.